Treatment of acute lymphoblastic leukemia (ALL) necessitates continuous risk assessment of leukemic disease burden as well as infections that arise in the setting of immunosuppression and myelosuppres
We describe a method for microscopic identification of DNA-synthesizing cells in bacterioplankton samples. After incubation with the halogenated thymidine analogue bromodeoxyuridine (BrdU), environmen
We report clinical outcomes of patients who received lyophilized FMT for primary and recurrent CDI and characterize bacteriome and mycobiome changes associated with therapeutic outcomes up to 6 months